Hansoh Pharmaceutical Group's (HKG:3692) HS-10561 capsules obtained China's National Medical Products Administration's approval for clinical trials to be tested for spontaneous hives, a Tuesday bourse filing said.
The capsules, Category 1 small molecule Bruton's tyrosine kinase inhibitor (BTKi) HS-10561, are jointly developed by the group and Guangzhou Lupeng Pharmaceutical.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.